

May 14, 2021

Dear Valued Healthcare Provider,

We hope this letter finds you well. First and foremost, we recognize and appreciate your continued commitment to public health through vaccination. We also want to thank you for choosing GSK as your Partner in Prevention.

We have an important contracting update to provide:

As of May 2021, GSK customers on a group/committed program will maintain their current contract pricing on PEDIARIX through the end of 2022*. There is no action required on your part – no signatures or contract amendments are needed, your current contract price will remain unchanged until the end of 2022.

Please contact your GSK representative or contract manager to discuss this update in more detail.

Again, thank you for all you do to protect patients.

Sincerely,

Judy Stewart Senior Vice President, US Vaccines

*Subject to contract terms and conditions

Trademarks are owned by or licensed to the GSK group of companies.

©2021 GSK or licensor. PDRLBND210009 May 2021 Produced in USA.